Charlotte S. Benartzi-Wilhelm

Cardiff, WLS CF144XN, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.

Journal: Cancers
Published: April 26, 2026

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.

Journal: Lancet (London, England)
Published: July 07, 2025

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Journal: Blood
Published: February 27, 2024

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 12, 2024

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Journal: Blood
Published: November 03, 2023

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.

Journal: Blood advances
Published: March 23, 2023

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

Journal: BMJ open
Published: December 08, 2021

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.

Journal: British journal of cancer
Published: June 11, 2020

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.

Journal: Blood advances
Published: March 20, 2019

Prediction of mode of delivery using the first ultrasound-based "intrapartum app".

Prediction of mode of delivery using the first ultrasound-based "intrapartum app".

Journal: American journal of obstetrics and gynecology
Published: January 17, 2019

Ultrasound is better tolerated than vaginal examination in and before labour.

Ultrasound is better tolerated than vaginal examination in and before labour.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology
Published: March 21, 2018

Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.

Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.

Journal: Cancer research
Published: June 06, 2017
Showing 1-12 of 29

Last Updated: 09/26/2026